Cybin Inc. (HELP)
NASDAQ: HELP · Real-Time Price · USD
12.81
+0.22 (1.75%)
Sep 29, 2026, 12:28 PM EDT - Market open
Cybin Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
100
Market Cap
935.90M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | - | - | - |
| Mar 31, 2025 | - | - | - |
| Mar 31, 2024 | - | - | - |
| Mar 31, 2023 | - | - | - |
| Mar 31, 2022 | - | - | - |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Rigel Pharmaceuticals | 276.79M |
| Arbutus Biopharma | 181.72M |
| Apnimed | 115.12M |
| Kura Oncology | 77.23M |
| Alumis | 7.40M |
| SL Science Holding | 3.27M |
HELP News
- 5 days ago - Psychedelic: Optimi completes psilocybin production for Phase 2 trial - TheFly
- 6 days ago - Cybin Transcript: TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit - Transcripts
- 6 days ago - Helus Pharma Announces Results of Annual and Special Meeting of Shareholders and Effective Date for Legal Name Change - GlobeNewsWire
- 7 days ago - Cybin Transcript: AGM 2026 - Transcripts
- 7 days ago - Helus Pharma to Participate at the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit - GlobeNewsWire
- 8 days ago - Helus Pharma presents new analyses on HLP003 in MDD - TheFly
- 8 days ago - Helus Pharma Presents New Analyses on HLP003 in Major Depressive Disorder at Psych Congress 2026 - GlobeNewsWire
- 8 days ago - Helus Pharma selloff Friday a buying opportunity, says Barclays - TheFly